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Background: The principal aim of this study was to investigate the long-term outcomes of a large cohort of
patients with ornithine transcarbamylase deficiency (OTCD) who were followed up at a single medical center.
Methods: We analyzed clinical, biochemical and genetic parameters of 90 patients (84 families, 48 males and 42
females) with OTCD between 1971 and 2011.
Results: Twenty-seven patients (22 boys, 5 girls) had a neonatal presentation; 52 patients had an “intermediate”
late-onset form of the disease (21 boys, 31 girls) that was revealed between 1 month and 16 years; and 11 patients
(5 boys, 6 girls) presented in adulthood (16 to 55 years). Patients with a neonatal presentation had increased mortality
(90% versus 13% in late-onset forms) and peak plasma ammonium (mean value: 960 μmol/L versus 500 μmol/L) and
glutamine (mean value: 4110 μmol/L versus 1000 μmol/L) levels at diagnosis. All of the neonatal forms displayed
a greater number of acute decompensations (mean value: 6.2/patient versus 2.5 and 1.4 in infants and adults,
respectively). In the adult group, some patients even recently died at the time of presentation during their first
episode of coma. Molecular analyses identified a deleterious mutation in 59/68 patients investigated. Single base
substitutions were detected more frequently than deletions (69% and 12%, respectively), with a recurrent mutation
identified in the late-onset groups (pArg40 His; 13% in infants, 57% in adults); inherited mutations represented half of
the cases. The neurological score did not differ significantly between the patients who were alive in the neonatal or
late-onset groups and did not correlate with the peak ammonia and plasma glutamine concentrations at diagnosis.
However, in late-onset forms of the disease, ammonia levels adjusted according to the glutamine/citrulline ratio at
diagnosis were borderline predictors of low IQ (p = 0.12 by logistic regression; area under the receiver operating
characteristic curve of 76%, p <0.05).
Conclusions: OTCD remains a severe disease, even in adult-onset patients for whom the prevention of metabolic
decompensations is crucial. The combination of biochemical markers warrants further investigations to provide
additional prognostic information regarding the neurological outcomes of patients with OTCD.
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Ornithine transcarbamylase deficiency (OTCD), an X-
linked disorder, is the most common urea cycle disorder
(UCD) with an incidence between 1/17 000 in the USA
[1] and 1/60 000 in Finland [2], whereas the overall fre-
quency of urea cycle disorders is approximately 1 in
8000 newborns [3]. The gene encoding OTC is located
on Xp21.1, and the enzyme is expressed in the liver and
gut. OTC is a mitochondrial enzyme that catalyzes the
conversion of ornithine and carbamoyl phosphate to
citrulline.
The clinical presentation of OTCD is very heteroge-
neous. Affected hemizygous males usually present in the
neonatal period with acute hyperammonemic coma due
to a severe enzymatic deficiency, whereas the clinical se-
verity of heterozygous affected females varies consider-
ably, depending partially on the pattern of inactivation
of the X chromosome. When the enzymatic deficiency is
partial, the onset of symptoms can be delayed to child-
hood or adult age for males and females. Hepatodiges-
tive, neurological or psychiatric symptoms can be
present. Biochemically, OTCD impairs the synthesis of
citrulline and urea, which leads to the accumulation of
ammonium, glutamine, and other amino acids, contrast-
ing with the low levels of citrulline and diversion of car-
bamoylphosphate into pyrimidine synthesis and leading
to an increase in the excretion of urinary orotic acid [4].
Until the early 2000s, diagnosis was confirmed by the
measurement of liver or gut OTC activity, followed
mainly by genetic mutation analysis of the OTC gene,
which is considered the reference test.
The principles of OTCD treatment are dietary protein
restriction, arginine and citrulline supplementation, and
the induction of nitrogen excretion via the administra-
tion of sodium phenylbutyrate and/or sodium benzoate
[5-7]. Liver transplantation is an alternative to medical
therapy for severe OTCD in the neonatal form, or in the
case of frequent episodes of recurrent hyperammonemia
or poor metabolic status [8,9].
Relatively little is known about the neurological and
metabolic evolution of treated patients with OTCD.
To better delineate the long-term outcome of patients
with OTCD, we analyzed clinical, biochemical, thera-
peutic, and genetic parameters as well as the outcomes
of a large cohort of patients who were reviewed over 40
years.Methods
Patients
Between 1971 and 2011, 90 patients (84 families, 48
males and 42 females) were diagnosed and followed up
for OTCD at Necker Enfants-Malades Hospital. The pa-
tients were born between 1939 and 2011.The inclusion criteria were that each patient had been
investigated in the same unit at Necker hospital and that
heterozygous females were symptomatic and had a con-
firmed OTC mutation or OTC enzymatic deficiency.
Patients with no confirmed enzymatic or molecular diag-
nosis were excluded, as were those who were diagnosed
at Necker Enfants-Malades hospital but followed-up in
another hospital.
We reviewed the neonatal presentations (0-30 days)
and late-onset phenotypes (after 30 days) separately. Re-
garding the late-onset group, we distinguished patients
who were diagnosed between 30 days and 16 years of
age (referred to as group 1 mth-16 y) from those who
were diagnosed after 16 years of age (referred to as
group >16 y).
In addition, asymptomatic carriers (relatives of pa-
tients) were studied at the molecular level.
The medical data were retrospectively obtained from
medical reports, including physical examinations, neuro-
psychological testing, nutritional parameters and drug
treatments. We recorded each hyperammonemic episode
and biochemical parameter at diagnosis and during the
follow up. We correlated the clinical presentation and
patient follow up to the biochemical and/or genetic data
for each patient.
This work was approved by our institutional ethical
committee after declaration to the Département de la
Recherche Clinique et du Développement, and informed
consent was obtained from the parents.
Clinical data
Clinical symptoms at diagnosis were classified into three
different phenotypes: neurological, hepatic, and psychi-
atric phenotypes.
Biochemical parameters
Multiple biochemical parameters were measured at
diagnosis, including peak ammonemia levels (N< 50 μmol/L),
plasma amino acids with glutamine (N: 530 +/- 81 μmol/L),
arginine (79 +/-25 μmol/L) and citrulline (N: 26+/-8 μmol/L),
and urinary excretion of orotic acid (N < 6 μmol/mmol
of creatinine).
Enzymatic and molecular diagnosis
The diagnosis was confirmed by measurement of the hep-
atic or intestinal OTC enzymatic activity [10] or by muta-
tion analysis of the OTC gene by direct sequencing of the
10 exons [11]. In cases in which no mutation was identi-
fied by sequencing analysis, multiplex ligation-dependent
probe amplification (MLPA) (SALSA MLPA P079
OTC kit, MRC-Holland, Amsterdam, The Netherlands)
was performed according to the manufacturer’s in-
structions [12,13].
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The medical treatment consisted of a low-protein diet
that was adapted to the tolerance of the individual com-
bined with arginine and/or citrulline supplementation
and sodium phenylbutyrate and/or sodium benzoate ad-
ministration, depending on the onset and severity of the
disease. Nocturnal enteral feeding was used for patients
with oral difficulties. Emergency treatment with high-
caloric intake providing glucose and lipids was per-
formed during catabolic states. Concerning neonatal
management, our practices improved over time through
the use of more effective hemofiltration since 2000, the
combination of intravenous sodium phenylacetate and so-
dium benzoate [7] and the systematic association of argin-
ine, citrulline, sodium benzoate and sodium phenylbutyrate.
Follow up: acute metabolic decompensations and
biochemical markers
The number of metabolic decompensations with clinical
symptoms and plasma ammonia concentration greater
than 100 μmol/L and/or hepatic failure requiring emer-
gency treatment and hospitalization were used to classify
the patients into three groups. Group 0 included none
or one metabolic decompensation during the follow-up
period. Group 1 included 2 to 10 episodes of decompen-
sation during follow-up and group 2 included at least 11
decompensations during follow-up.
The biochemical markers measured during follow-
up excluded those corresponding to acute metabolic
decompensations.
Neurological outcome
The psychomotor evaluation was performed using stan-
dardized psychological tests according to the age of the
patient: the developmental quotient (DQ) by the Brunet-
Lezine test; the intellectual quotient (IQ) by WPPSI-R
and WPPSI-III (Wechsler Preschool and Primary Scale
of Intelligence); WISC-III and WISC-IV (Wechsler
Intelligence Scale for Children). Two others tests were
used in a subset of cases: NNAT (Naglieri Non-Verbal
Ability Test) and NEMI (New Intelligence Metrical Scale).
The other criteria used to assess the neurological out-
come were the schooling of the patient, which was clas-
sified as normal with normal academic achievement for
age, in remedial classes or institutional education if the
patient had a minor handicap, and no schooling in the
presence of severe mental retardation. For adults, we in-
vestigated socio-professional integration and autonomy.
We established a neurological score based on the fol-
lowing parameters: intellectual performance adapted to
age, academic achievement and motor disorder with lim-
ited autonomy. Patients were classified into group 1 if
they had an estimated IQ > 80 with normal academic
achievement, group 2 if they had moderate mentalretardation (50 < IQ < 80) and neurological sequelae
leading to institutional education, and group 3 if they
had severe mental retardation (IQ < 50) and neurological
damage with no motor autonomy.
Statistical analysis
The results are expressed as the mean and median
values (with minimum-maximum range values) for
quantitative data and as percents for categorical data.
Comparisons of categorical data were performed using
Fisher’s exact test. Overall survival was calculated from
birth to last follow-up or death and was estimated using
the Kaplan-Meier method. Statistical significance was set
at p < 0.05. Survival, area under the curve, and linear
and logistic regression analyses were performed with
survfit, pROC and glm modules in R (http://cran.r-pro-
ject.org/).
Results
Among the 90 patients with OTCD, 53% (48 patients)
were males and 47% (42 patients) were heterozygous
symptomatic females. Twenty-seven patients (30%) were
diagnosed with a neonatal presentation, including 22
males (81%) and 5 girls (19%). The median age at diag-
nosis was 2 days, after the exclusion of 6 asymptomatic
patients who were treated immediately after birth due to
a prenatal diagnosis that followed an index case in the
corresponding families. Fifty-two patients (58%) had a
late-onset form of the disease that was revealed between
1 month and 16 years (median age at diagnosis: 1.3
years), including 31 girls (60%) and 21 males (40%).
Eleven patients (11%) presented disease in adulthood
and adolescence after 16 years of age (median age at
diagnosis: 28 years), including 5 males and 6 girls (cf
Table 1).
Mortality
Mortality was much higher in the neonatal group (20/27
or 74% deceased at diagnosis or during follow-up) than
in the late-onset forms (8/63 or 13% deceased overall,
p < 0.0001; cf Figure 1). In fact, mortality reached 90%
in the neonatal-onset group when the 6 patients diag-
nosed antenatally were removed from this group. As
summarized in Table 1, in the neonatal group, 13 pa-
tients died early in the neonatal period; 3 died after
postoperative liver transplantation at 3.5 years of age; 1
died of Reye syndrome at 4 years of age; and 3 died
after infection with neurological signs and coma, and
psychiatric signs in one patient, at ages 2, 6, and 7
years. To summarize, 60% of the cases with a neonatal
presentation died at presentation, and 75% of the survi-
vors subsequently died between 1 and 7 years of age. In
the late-onset forms of the disease, 6 patients died at
presentation during the first acute metabolic crisis
Table 1 Epidemiological characteristics of the patients
Neonates Group 1 m-16y Group >16y
Number of cases 27 52 11
Males 22 21 5
females 5 31 6
Number of deceased 20 7 1
at diagnosis 13 5 1
during follow up 7 2 0
Number of decompensations per patient (and relative to mean length of follow-up)* 6,2 (1.0/yr) 2,5 (1/10 yrs) 1,4 (<1/20 yrs)
Neurological score (IQ) at last follow up, N > 80 90 92 Normal socio-professional
insertion
Mean peak plasma ammonia at diagnosis (μmol/L), N < 50 μmol/L 960 500
Mean plasma glutamine at diagnosis (μmol/L), N: 530 +/- 81 μmol/L 4110 1000
Plasma citrulline at diagnosis (μmol/L), N: 26+/-8 μmol/L 5 15 14
*Only the patients that survived beyond neonatal life were included.
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with a diagnosis of fibrolamellar hepatocellular carcin-
oma that was resistant to chemotherapy (her OTCD
was diagnosed at age 11); and 1 girl died at 4 months of
age after an infection that led to a hyperammonemic
coma. This result indicates that for the late-onset form,
deaths were rare during infancy, whereas a peak in
mortality occurred at adolescence (9-14 years) in the 1
mth-16 y group (Figure 2; Fisher’s exact test, p < 0.01).
Clinical presentation
The clinical presentation was homogenous in the
neonatal-onset group, with lethargy, failure to thrive and
vomiting that led to a hyperammonemic coma in 21
symptomatic patients. For the patients in the 1 mth-16 y
group, the symptoms were quite variable (Table 2). TheFigure 1 Survival of OTCD patients by age of onset. Comparison of surviva
group, the “critical” period (risk of death) is that between the first severe sy
age intervals: the first days of life and the period between 1 and 7 years offirst symptoms were mostly neurological (49/52 patients)
and included alterations in consciousness (31/52), global
hypotonia (10/52), ataxia (2/52), and acute neurological
regression (2/52). Three patients presented a sudden
neurological deficit (hemiparesis) that was associated
with seizures and fever referred to as stroke-like epi-
sodes at the ages of 6, 10 and 27 months. A pre-existing
history of recurrent vomiting (3/3) and developmental
delay (2/3) was retrospectively noted. Recurrent vomit-
ing was frequently associated with the neurological
symptoms (42/52 patients), whereas acute hepatic failure
and/or Reye syndrome were less frequent (23%). Psychi-
atric symptoms were the primary presenting factors in
21% of the cases and involved abnormal behavior and
confused states with hallucinations over time and disori-
entations in space. Nevertheless, in all of the cases,l between the 1 mth-16 y and neonatal group. In the 1 mth-16 y
mptoms and diagnosis. In the neonatal form, there are two high-risk
age.
Figure 2 Age at diagnosis, length of follow-up, and mortality in the 1 mth-16 y group. A peak of mortality was noted approaching and
during adolescence.
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apparent, as detailed in the next section.
All of the patients in the group > 16 y presented
neurological signs at diagnosis (alteration of conscious-
ness). Four of 11 patients presented with hyperammone-
mic coma, and 2 died recently at their first episode,
including one as recently as 2011. Six of 11 patients had
digestive signs (vomiting), but the psychiatric symptoms
led to the diagnosis in 4/6 and again were consistently
associated with neurological symptoms. A pre-existing
history of chronic headaches (3/11) and repeated epi-
sodes of unexplained hepatitis (2/11) was retrospectively
noted. Not surprisingly, 7/11 patients in the group > 16 yTable 2 Clinical presentations of 90 patients with OTC deficie
Initial symptoms Neonatal-onset form
(n = 27)
Coma 21






hemiparesis (« stroke-like »)
Digestive and Hepatologic signs
recurrent vomiting
Reye’s syndrome
Psychiatric symptomshad an aversion to protein and spontaneously consumed
a vegetarian diet.
Decompensations
The number of decompensation episodes varied between
the patients with the neonatal form who survived be-
yond the first week of life (14/27; actual mean age of
10.5 years for the 6 survivors in 2011) and those in the 1
mth-16 y group (actual mean age of 17 years for the pa-
tients who were alive in 2011). Three patients with a
neonatal-onset had a score of 0 (patients with a prenatal
diagnosis), seven patients had a score of 1 and three pa-
tients had a score of 2. The youngest patient was notncy
Late-onset form (1 m-16 y) Adults (>16 y)
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because he was 6 months old with normal development
and had not yet experienced decompensate. The mean
number of decompensations in this group was 6.2 (0-20).
In the 1 mth-16 y group, 26 patients had a score of 0, 10
patients had a score of 1 and only 3 patients had a score
of 2. The mean number of decompensations in this group
was 2.5 (0-14). The difference was statistically significant
between the two groups (Fisher’s exact test, p = 0.028). For
patients in the group >16 y, the mean number of decom-
pensations was 1.4 (0-3) (actual mean age of 44 years for
the surviving patients in 2011). The survival rate might be
related to the number of decompensations in the neonatal
group, whereas in the 1 mth-16 y group, there was no re-
lationship between the survival and frequency of decom-
pensations (data not shown). Triggering factors for young
patients or patients in the 1 mth-16 y group were primar-
ily weaning from breastfeeding and/or dietary diversifica-
tion (45%); infections were frequent (30%), and other
triggers were less frequent: surgery (2 cases), sodium
valproate (1 case), and vaccinations (2 cases). For pa-
tients > 16 y, 5/11 (45%) presented acute metabolic de-
compensation after an increase in protein intake during
a meal. One woman had digestive symptoms with
hyperammonemia post-partum.
Neurological outcome
Five patients with a neonatal-onset had a median IQ =
90 (67-91) at ages 14 months, 16 months, 26 months, 5
years and 11 years. Three of the five patients are still
alive at ages 3, 4 and 14 years. Among the surviving
school-aged children, three had normal schooling and
two had remedial schooling due to specific learning dis-
abilities (dyslexia, deficits in executive function, atten-
tion deficit or hyperactivity).
In the 1 mth-16 y group, 20 patients between 2 and 12
years had a median IQ = 92 (55-103) (we considered the
latest test for each patient). Among 38 patients in this
group whose developmental outcome and schooling were
precisely documented, 27 had normal schooling (71%), 5
had no schooling (13%) due to severe neurodevelopmental
disabilities (severe epilepsy and mental retardation) and 6
had remedial schooling (16%). The two youngest patients
(2 years old) were not yet documented because of their
young age and were strictly normal. The mean neuro-
logical score for this group was 1.28 (n = 38) with 10 pa-
tients in group 2, whereas the mean neurological score in
the neonatal group was 1.20 (n = 6) with only 1 patient in
group 2. There were no statistically significant differences
in the neurological scores between the neonatal-onset
group and the 1 mth-16 y group. No significant correl-
ation was detected between the neurological score and
either the ammonia peak at diagnosis or the plasma glu-
tamine concentration at diagnosis (data not shown).Finally, among all of the adult patients at the time of
the study, 7 were diagnosed during the neonatal period
or childhood, and 9 were diagnosed in adulthood. All of
the adults had good socio-professional and economic inte-
gration and seven had children, including one woman
who had undergone liver transplantation at 6 years of age.
Biochemical parameters at diagnosis
The mean peak of ammonemia at diagnosis was much
higher in the neonatal group after the exclusion of the
patients who were diagnosed antenatally (mean value =
960 μmol/L and median value = 925 μmol/L) than in the
pooled late-onset groups (mean value = 500 μmol/L and
median value = 240 μmol/L). The plasma glutamine
levels at diagnosis correlated with the ammonia levels
and were much higher in the neonatal group (mean and
median values = 4110 μmol/L) than in the late-onset
groups (mean and median values = 1000 μmol/L) Figure 3.
The degree of plasma citrulline depletion was more
marked than that of plasma arginine in all of the patients
(data not shown). The plasma concentration of citrulline
was lower in the neonatal group (median value = 5 μmol/L
and undetectable in 8 patients) than in the late-onset
groups (median values = 15 μmol/L in patients in the 1
month – 16 year group and 14 μmol/L in patients in the
greater than 16 year group). There was no correlation be-
tween the biochemical parameters at diagnosis (plasma
ammonia, glutamine and citrulline) and the neurological
outcome in the 1 m-16 y group (Figure 4a). Therefore, in
patients with the late-onset form (1 mth-16 y), we
attempted to combine three relevant biomarkers into a
predictive score by regressing the plasma ammonia levels
on the glutamine/citrulline ratio (intended as a better indi-
cator of the glutamine response to ammonia rather than to
other factors such as the fasting time). The resulting resid-
uals can be rationalized as the among-patient variation of
ammonemia relative to the glutamine levels, with higher
values representing a reduced capacity to incorporate
ammonemia into glutamine. The values for this score at
diagnosis were borderline predictive of IQ, with an odds
ratio of 3.3 (0.7 -14.5; p = 0.12) and area under the receiver
operating characteristic curve of 76% (p < 0.05; Figure 4b).
We also investigated potential correlations between
plasma markers at diagnosis and survival, and we found
no differences in the ammonemia or glutamine levels
between patients with a neonatal presentation that sur-
vived less vs those that survived more than 1 week (left-
most columns in Figure 5a and 5b). The late-onset forms
had reduced levels of glutamine and ammonemia, with
potentially moderately higher levels in the group of pa-
tients who died during adolescence (Figure 5, yellow bar
labeled as “5-15 y dead” compared to the pale blue bars).
The excretion of urinary orotic acid was very high at












Neonatal Group Late onset group
960 µmol/L vs 500 µmol/L
4110 µmol/L vs 1000 µmol/L
500 µmol/mmol  creat  vs N 
except one patient (200 
µmol/L)
Figure 3 Comparison of biochemical parameters at diagnosis (plasma ammonemia, plasma glutamine and urinary orotic acid) in the neonatal
group versus the late-onset groups (1 mth-16 y and >16 y groups).
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approximately 500 μmol/mmol. By contrast, the adult
patients displayed normal urinary orotate excretion at
the time of diagnosis (<6 μmol/mmol creatinine), ex-
cluding one patient (urinary orotic acid of 200 μmol/
mmol creatinine).
In 4 cases, we measured the glutamine level in the
cerebrospinal fluid (CSF) concomitant with the plasma
glutamine. Four patients (6 months, 6 months, 4 years,
and 19 years old) had very high CSF glutamine (2500-
7482 μmol/L) levels compared to their plasma glutaminea
Figure 4 Initial plasma markers (plasma ammonemia, glutamine and citrul
mth-16 y group. Cognitive outcome was based on an IQ < 80 or >80, revea
outcomes. a: Individual markers shown separately (in μM). b: A combined s
a borderline predictor of IQ in the 1 mth-16 y group (see text).levels (500-4500 μmol/L) during acute metabolic decom-
pensations in which ammonemia was subnormal or
moderately high, suggesting that neurological symptoms
and cerebral edema were caused by an increase in brain
glutamine. In a fifth patient aged 40 years, CSF glutam-
ine had also been collected a few days after a metabolic
decompensation that occurred during follow-up (1857
μM), but no plasma was collected at that time. Figure 6
compares the 4 cases with paired plasma/CSF glutamine
determinations to the paired samples from other urea
cycle defects and to a reference hospital cohort of 562b
line) compared to the control group and cognitive outcome in the 1
ling extensive overlap of the values among patients with different




Figure 5 Biochemical markers in the different groups of patients with different clinical forms based on age at diagnosis as indicated. a: Plasma
ammonia in μM. b: Plasma glutamine in μM. Red circles indicate female patients, and blue circles are male patients. The boxed color codes are
approximate indications of the clinical severity (blue: moderate; yellow: severe; red: early severe).
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found that the level of CSF glutamine was systematic-
ally much higher in OTCD and other UCD relative to
the reference population (as summarized by the black
vs the blue regression lines in Figure 6). Thus, com-
pared to plasma glutamine, CSF glutamine may repre-
sent an additional marker for the diagnosis of defects in
the urea cycle. Nevertheless, among patients withFigure 6 Biplot of CSF (Y-axis) vs plasma (X-axis) glutamine in paired samp
the reference hospital population, and colored circles represent urea cycle
urea cycle disorder, the blue solid line is the regression line for the referen
less than 1000 μM), and the dotted line is the theoretical equality line betwOTCD and urea cycle disorders, CSF glutamine varied
linearly with plasma glutamine (upper regression line in
Figure 6; r-squared = 0.86). Thus, CSF glutamine ap-
pears to be as informative as plasma glutamine during
follow-up. However, because of the small sample size,
we cannot exclude the possibility that some of the pa-
tients with UCD may show normal CSF glutamine
levels at presentation.les from our hospital cohort (bilog transformation). Empty circles are
disorders as indicated. The black solid line is the regression line for
ce population (calculated based on samples with CSF glutamine levels
een the CSF and plasma.
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In a heterozygous OTCD female, which is often but not
always identified among the relatives of probands, we
found a broad spectrum of symptoms ranging from pro-
tein aversion and behavioral disabilities, making it difficult
to distinguish between symptomatic and asymptomatic
carriers. Most of these heterozygous female patients
(approximately 80% in the literature) are apparently
asymptomatic and present a normal biochemical workup
(notably, ammonemia and plasma glutamine). In our co-
hort, among the asymptomatic carrier females, only 2/25
had abnormal peak urinary orotate (>10 μmol/mmol of
creatinine), and 7/18 had a positive protein loading test
with increased acid orotic excretion in the urine and/or
high ammonemia in the plasma. These loading tests and
the allopurinol test are not used for the diagnosis of
asymptomatic females due to the lack of sensibility, and
genetic analysis is currently the screening tool used to
diagnose female carriers. Because these asymptomatic
carrier females were healthy, exhibiting no decompen-
sation during environmental-related stress episodes
(fever, gastroenteritis, surgeries, deliveries) and normal
biochemical data under baseline conditions, no treat-
ment was proposed. However, an emergency certificate
was provided to manage any symptoms related to acute
metabolic stress situations.
Biochemical and therapeutic follow up
Regarding the long-term biochemical follow up, ammo-
nia levels were normal in the absence of episodes of
decompensation (<50 μmol/L). We analyzed plasma glu-
tamine and urinary orotic acid independently of acute
metabolic decompensations for each patient with a
follow-up between 3 and 14 years after diagnosis. The
mean and median glutamine values were approximately
800 μmol/L (548-1123) for all of the patients. The urin-
ary orotic acid measurements revealed a large range of
inter- and intra-individual variability, with mean and
median values of 20,6 μmol/mmol (2,5-115) and 10
μmol/mmol of creatinine, respectively. Furthermore, the
levels of plasma glutamine and orotic acid did not cor-
relate within the same patient.
Concerning the long-term management, surviving pa-
tients in the neonatal-onset group after the neonatal
period were treated with a low protein diet (mean 1 g
protein/kg/day at one year of age for 8 patients, three
years of age for 4 patients and six years of age for 4 pa-
tients). Three patients required nasogastric enteral feed-
ing. In the 1 mth-16 y group, the mean total protein
intake was 1.3 g protein/kg/day at one year and then di-
minished to 1.1 g protein/kg/day at three years and 0.9 g
protein/kg/day at six years. Nasogastric enteral feeding
was required for 10 patients (20%) due to anorexia (8/10)
and to neurological sequelae with deglutition disorder(2/10). For patients > 16 y, a low protein diet was not
systematically implemented (i.e., 75% of the patients);
the diet was moderate with spontaneous protein restric-
tion to approx. 35 to 50 g protein/day.
Arginine supplementation was given without citrulline
in 42% of the neonatal patients and 30% of the late-
onset groups, citrulline alone in none of the neonatal pa-
tients and 28% of late-onset groups and both arginine
and citrulline in 70% of the neonatal patients and 23% of
the late-onset groups. Arginine and citrulline were com-
bined with the ammonia scavengers oral sodium benzo-
ate for only 50% of the patients in neonatal group and
38% of the patients in late-onset groups; sodium phenyl-
butyrate was never used alone in late-onset groups and
in only 10% of the neonatal patients. These treatments
were used in association in 40% of the patients in the
neonatal group and 23% of the patients in the 1 mth-16
y group (not in patients >16 y).
Among patients with the neonatal form of the disease,
two boys and one girl underwent liver transplantation at
three and a half years of age but died during the imme-
diate postoperative period due to surgical complications
(acute transplant rejection, vascular complications and
acute tacrolimus toxicity). In the late-onset group, two
girls underwent orthotopic liver transplantation from a
cadaveric donor at three and a half and six years of age.
The indications for liver transplantation were recurrent
acute episodes of hyperammonemic decompensation
despite aggressive dietary and therapeutic treatment.
Those who survived beyond the postoperative period are
alive at age 19 and 25 years at the end of the study.
Among the adult patients, only one female was preg-
nant. The delivery was medically assisted (intravenous
sodium benzoate, arginine, glucose and lipids) with no
complications. Her daughter, an affected infant, is now
treated in the unit.
OTC activity and mutation analysis
The diagnosis was confirmed by the measurement of
hepatic (16 patients) or digestive (21 patients) OTC en-
zyme activity and/or by mutation analysis (68 patients
investigated). OTC enzyme activity was undetectable in
the neonatal-onset group (8 patients). In the late-onset
groups, 29 biopsies (13 liver biopsies and 16 intestinal
biopsies) revealed a mean value of residual OTC enzyme
activity of 11% (2-25%). Molecular diagnosis by direct
sequencing of the ten exons identified a deleterious mu-
tation in 60/68 patients (88%), with 43 different muta-
tions (Table 3). In the neonatal group, 63% (14/22) of
the mutations were single-base substitutions, whereas
the remaining mutations were complete deletions (18%,
4/22) or mutations affecting consensus splicing sites
(18%, 4/22). No prevalent mutations were noted in this
group. In the late-onset forms, single base substitutions
Table 3 Deleterious mutations in OTC genes
Neonatal-onset form Group (1 mth-16 y) Group >16 y Carriers
Deleterious mutations 22 30 7 52
10 F / 42 M
• Single base substitution 14 21 6
• Small deletions 0 3 1
• Large deletions 0 3 0
• Complete deletions 4 0 0
• Splice site mutations 4 3 0
Recurrent mutations R40H :0 R40H :4 R40H :4 R40H :20
T178M :1 M T178M :2 F T178M :1 F T178M :6 F
De novo mutations 8 10 4
X-linked mutations 14 20 3
Mutations transmitted by father 0 0 0
M: male; F: female. NB: two families with asymptomatic fathers who transmitted R40H mutations to their asymptomatic daughters.
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remaining mutations were large and small deletions
(19%, 7/37) and splice site mutations (8%, 3/37). One
mutation has been described previously to confer a late-
onset type of presentation [14]: c.119 G>A (single base
substitution: pArg40His in exon 2 or R40H). This muta-
tion was recurrent and was detected in 13% of the 1
mth-16 y group (4/30) and 57% of the group >16 y (4/7).
Thus, the mutations in the neonatal and late-onset
groups were distinct.
Half of the mutations were inherited in males in the
neonatal group and in the 1 mth-16 y group. In females,
mutations were inherited in 60% of the neonatal group
and in 24% of the 1 mth-16 y group. In all of the pa-
tients, 1/3 mutations were de novo and 2/3 mutations
were X-linked inherited mutations without differences
between the groups.
Discussion
Here, we report a series of 90 patients with OTCD, of
which 30% had a neonatal and 70% had a late-onset
form (revealed at ages 1 mth-16 y or >16 y). The gender
distribution was not equivalent between boys and girls,
as expected from an X-linked disorder, and therefore,
81% of the neonatal cases involved boys, whereas girls
presented more frequently during childhood [15]. The
survival rate was 30% in the neonatal forms, which is
comparable to a previous study [15], and decreased to
10% with the removal of the patients who were diag-
nosed prenatally. However, only eight neonates in our
series were born after the year 2000 as a consequence of
progress in intensive medical therapies along with im-
proved hemofiltration [7] and liver transplantation.
However, presymptomatic therapy may improve neo-
natal survival (100% vs 40%, p = 0.06) and long-term sur-
vival (50-75% vs 10%, p = 0.11). It is also important toconsider that some adults still die during their first
metabolic coma because of a delayed diagnosis [16], thus
emphasizing that adult intensive care unit physicians
should have a greater awareness of the presentations of
late-onset forms of inherited metabolic diseases.
Variable clinical presentation: is OTC deficiency still
underdiagnosed?
The OTCD phenotype ranges from neonatal or adult
death (hyperammonemic coma) to various hepatic, psy-
chiatric and neurological symptoms including gastro-
intestinal dysmobility. Several adults experienced their
first symptoms as late as 60 years of age [17], but they
were likely to represent only a fraction of a larger pool
of affected adults. The most suggestive symptoms are
neurological (lethargy, ataxia, hypotonia, confusion, head-
ache) associated with recurrent vomiting (gastrointestinal
dysmobility, a neurological symptom). Although rare in
our series, focal neurological sign such as hemiplegia and
stroke-like episodes can also occur [5], which may be due
to alterations in vascular endothelial wall integrity and in
cerebral perfusion [18]. Psychiatric symptoms were rela-
tively common in our cohort but were always associated
with other neurologic or digestive signs. Nevertheless, psy-
chiatric symptoms were the leading cause of consultation
in several cases, suggesting that the diagnosis of OTCD
may still be underdiagnosed. Overall, we advocate that ir-
respective of age, any individual with an encephalopathic
illness, psychiatric symptoms, stroke-like episodes or sus-
picion of exogenous intoxication should undergo prompt
blood ammonia estimation due to the possibility of a diag-
nosis of OTCD [19].
Neurological outcome of surviving patients
Concerning the neurological outcome in surviving pa-
tients, we obtained satisfying results for the IQ/DQ tests
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ducted at the same age for all patients (IQ 90 to 92 for
tested patients, normal schooling for most patients and
normal socio-professional insertion for adults). Like
others before us [20,21], we found that prospectively
treated children (antenatal diagnosis) had a better neuro-
logical outcome because the management of the first
acute coma is crucial.
We did not perform neurocognitive testing of the ap-
parently asymptomatic female carriers, although some of
them appeared to be emotionally fragile and emotive.
Previous studies have identified some degree of neuro-
logical disability. In Gyato’s study [22], comprehensive
neuropsychological testing was conducted in 10 mildly
symptomatic and 9 asymptomatic heterozygous women.
Among the group, these women had average IQ scores
and displayed specific neuropsychological phenotypes
with significant strengths in verbal intelligence, verbal
learning, verbal memory and reading. In contrast, they
scored significantly lower than the normative sample for
nonverbal and fine motor functions. The asymptomatic
subgroup outperformed the symptomatic subgroup in all
of the tested domains.
At the other end of the spectrum, we identified 10
asymptomatic boys among the relatives of the probands
who could have mimicked dominant inheritance with in-
complete penetrance.
Biochemical parameters
Significant differences were found for the plasma ammo-
nia concentration at diagnosis, with mean values of ap-
proximately 960 μmol/L in the neonatal group and
approximately 250 μmol/L in the late-onset groups,
which is consistent with previous studies [14]. There are
very little data in the literature concerning other biochem-
ical markers. Regarding plasma glutamine, Tuchman’s
study [23] showed a mean value of 859 μmol/L, which
was much lower than the value obtained in our study
(mean value of 4110 μmol/L in the neonatal-onset group
versus 1000-1500 μmol/L in the late-onset forms). In
addition, the mean values for plasma citrulline were much
lower than in Tuchman’s cohort (15 μmol/L versus 29
μmol/L). These differences were related to the smaller
proportion of neonatal patients and the large number of
asymptomatic females with normal values in Tuchman’s
group. Only the arginine concentration showed similar
values in the two cohorts.
In other studies [7,24] as well as in ours, there was a
significant correlation between survival and the peak
level of ammonium. In our cohort, survival was signifi-
cantly improved when peak ammonium levels were less
than 500 μmol per liter compared to more than 1000
μmol per liter (p < 0.001, Fisher’s exact test). Among the
eleven patients (10 neonates and 1 infant) with peakammonium levels greater than 1000 μmol/L, 10 died
within the few days following the hyperammonemic epi-
sode (survival: 9%), whereas among the 46 patients with
peak ammonium levels less than 500 μmol/L, survival
was significantly improved (survival: 90%).
In the 25-year retrospective cohort of Enns [7], which
included 299 patients with urea cycle disorders with epi-
sodes of hyperammonemia, the overall survival was 84%
with a combination of intravenous phenylacetate and so-
dium benzoate therapy (Ammonul®). Nevertheless, pa-
tients who were younger than 30 days of age with a peak
of ammonium level above 1000 μmol/L were the least
likely to survive a hyperammonemic episode (38%) des-
pite the use of drugs and hemodialysis. By contrast,
there were no significant correlations between the
plasma glutamine concentration at diagnosis and the
neurological outcome in our cohort. Nevertheless, a
combined “score” reflecting excess plasma ammonia
levels that were normalized to glutamine as measured at
diagnosis (see Results section above) was a borderline pre-
dictor of low IQ in late-onset OTCD (OR: 3.3; p = 0.12;
and AUC: 76%, p < 0.05). This score was meant to meas-
ure the ammonia-scavenging capacity of glutamine: the
greater such a “normalized difference” between ammonia
and glutamine, the lower was the inferred ammonia scav-
enging capacity. It will be interesting to further evaluate
whether this score or any other parameter combining am-
monia and amino acid levels may improve prognosis or
follow-up.
The presence of glutamine in plasma does not fully re-
flect the concentration of glutamine in CSF [25] and in
brain tissue. Ammonia enters the brain via diffusion
from the blood or cerebrospinal fluid, or it is formed in
situ from the metabolism of endogenous nitrogen-
containing substances. In the brain, glutamine synthetase
confined to astrocytes increases the formation of glu-
tamine from ammonia, generating an osmotic stress that
compromises astrocyte function and morphology and
leads to neuronal dysfunction (« the osmotic gliopathy
theory »).
We found that the levels of CSF glutamine were sys-
tematically elevated in all 4 tested patients with OTCD
as well as in patients with other UCD compared to the
complete hospital cohort, and this finding contrasted
with plasma values that largely overlapped with the
normal/reference values (Y vs X axis in Figure 6).
Otherwise, the CSF and plasma glutamine values were
highly correlated in these patients (r-squared of 86%,
Figure 6). Thus, it is unclear whether CSF glutamine
provides added value compared to plasma glutamine in
patients with known UCD, whereas it likely provides in-
formation for diagnostic purposes. Because glutamine
tends to increase as a first-line buffer against ammonia
accumulation, it is an important early marker of UCD
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glutamine to other amino acids, notably citrulline (cf.
Figure 4), may be preferable to control for confounders
such as the sensitivity of amino acid levels to the fasting
status.
Therapeutic strategies
The standard therapy used for acute hyperammonemic
episodes includes ammonia scavengers (intravenous or oral),
arginine and citrulline supplementation, and hemodialysis.
However, no consensus or established protocol is cur-
rently available, and thus, our data reflect our own
practices. Moreover, our practices have changed over
time: the neonatal patients are now usually treated with
both arginine and citrulline and with ammonia scaven-
gers including the combination of intravenous sodium
phenylacetate and sodium benzoate, according to the
European protocol to which we have contributed [7]. In
2013-2014, the three neonates we cared for at birth for
OTCD and who were not included in this report, were
successfully resuscitated by medical management (data
not shown, see below).
In addition, liver transplantation is an option for the
management of patients with severe urea cycle disorders,
in particular patients who present neonatally or those
with poor metabolic control and recurrent episodes of
decompensation despite optimal medical treatment. In
our series, three deaths among five patients who under-
went liver transplantation occurred during the early
postoperative period due to technical problems (acute
transplant rejection, vascular complications and acute
tacrolimus toxicity). In addition, we recently changed
other practices (surgery, intensive care, anesthesia),
which may explain the increased rate of success. For ex-
ample, among the three neonates who were recently
born and not included in this series, two successfully
underwent liver transplantation at ages 9 and 6 months.
In a review of the current role of transplantation for the
treatment of urea cycle disorders [26], the overall cumu-
lative patient survival rate was found to be more than
90% at 5 years (6 deaths among 51 patients). Among
other groups, experience in Japan shows that systematic
aggressive liver transplantation for OTCD patients diag-
nosed at birth since 1995 has improved survival from
10% to currently 90% [27]. Although the reported suc-
cess rate may be slightly inflated by the inclusion of pa-
tients who benefited from a prenatal diagnosis and thus
preventive therapy at birth, these studies show that liver
transplantation has dramatically improved the survival
of neonatal-onset OTCD patients. In France, based on
these results, the indications for liver transplantation are
currently being extended. Nevertheless, practitioners are
still concerned about the quality of life of the trans-
planted OTCD patients. Moreover, limited resources,including the supply of donor livers, may restrict liver
transplantation options. An alternative therapy for urea
cycle disorders may be hepatocyte transplantation. How-
ever, all of the biochemical and clinical corrections de-
scribed to date appear to have been transient, and
hepatocyte transplantation was followed by liver trans-
plantation [28]. Finally, hepatocyte transplantation could
be used in conjunction with auxiliary partial orthotopic
transplantation as an effective treatment for severe
OTCD patients and likely improve neurodevelopmental
outcomes [29].
Diagnostic confirmation
Molecular analysis is now regarded as the reference test
for the identification of private mutations within fam-
ilies. This technique is not invasive, in contrast to the
liver or intestinal biopsies required for enzyme assays,
and patients with mild disease and asymptomatic rela-
tives of patients are being diagnosed with increasing fre-
quency [14]. In the literature, only approximately 50 to
80% of patients with OTCD have an identifiable point
mutation based on sequencing analysis [14,30]. In our
cohort, we identified 87% of the deleterious mutations.
Only 9/68 patients had negative molecular results but a
reduced OTC enzyme activity. Most mutations in OTC
genes were private and specific to a family, and more
than 340 mutations are known to cause OTC deficiency
[30]. The most frequent mutations in our cohort were
single base substitutions (70%) as described previously
[14], and mutations have been found in all of the exons
and introns of the OTC gene. Among single nucleotide
substitutions, substitutions of G to A and C to T were
much more frequent than any other substitution, as ob-
served in the « recurrent » R40H mutation (c.119 G>A)
and the T178M mutation (c.533C>T). This finding can
be explained by the mutagenic CpG dinucleotide
(methylation-induced deamination). Large deletions and
deletions of the entire gene were more frequent (12%)
than in the others studies [14,30] (approximately 5%),
but multiplex ligation-dependent probe amplification
(MLPA) analysis was systematically performed in our
series. Thus, deletions should be searched by array com-
parative genomic hybridization (CGH array) or MLPA in
the case of negative OTC sequencing in patients with
symptoms of the disease [13,31]. OTC deletions can be
of various sizes (intragenic deletions of one or more
exons or deletions of the entire gene) [32]. It is import-
ant to note that the 4 complete deletions of the OTC
gene were observed in the neonatal presentation. Muta-
tions affecting the consensus splice site represented
approximatively 12% of the total mutations, which is
consistent with the McCullough report. In the litera-
ture, consensus splice site mutations appear to confer a
severe neonatal-onset phenotype. In our series, two
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quences (IVS7+3A>G and IVS5a A>G) were previously
described to confer a severe neonatal phenotype and
were identified in two females herein with a late-onset
presentation. The remaining 5 to 10% of the patients
without a mutation (neither large deletions nor point
mutations) could carry mutations in regulatory do-
mains (promoter or enhancer) or intronic regions of
the OTC gene, or they could have mutations in other
genes that confer a phenocopy of OTCD.
Several mutations found in asymptomatic adults or
adults with a mild phenotype were also detected in chil-
dren with a severe phenotype. This finding suggests that
OTC deficiency is a highly pleomorphic, semidominantly
inherited disorder in which other genetic and environ-
mental factors such as catabolic events play an import-
ant role. Despite a better understanding of the normal
function and assembly of OTC, it remains difficult in
some cases to predict what phenotype to expect for a
particular mutation. Interestingly, OTCD was initially
assumed to be transmitted by females only as an X-
linked disorder. However, only half of the mutations (for
example T178M, R92C and G39C) were inherited in
males in the neonatal group. We identified adult males
with partial OTCD, some of which were asymptomatic,
but they transmitted their mutation to their asymptomatic
daughters, such as R40H and A208T mutations. Overall, it
is very important to identify the mutation carried by the af-
fected patient and then to screen the entire family (carrier
testing and prenatal diagnosis) to identify asymptomatic
relatives. Preventive measures are important for relatives
because death can still also be associated with late presen-
tations of the disease. Thus, genetic screening is crucial for
the prevention of acute decompensation in relatives.
Conclusion
Despite medical progress and prompt diagnosis, morbid-
ity and mortality have remained unsatisfactorily high in
the neonatal group of our cohort, but by analogy with
other countries, mortality should decrease as hepatic
transplantation becomes a more consensual indication
for this disease in France. In the adult group, death may
still occur during the first episode of decompensation
due to a delayed diagnosis. Thus, we strongly emphasize
that critical care clinicians be aware of the crucial need
for early diagnosis in patients with adult-onset OTC. Al-
though survival differed between clinical forms and cor-
related with lower ammonia and glutamine levels, the
neurological outcomes of the survivors did not correlate
with hyperammonemia or plasma glutamine levels at
diagnosis. Mutations were only partly correlated with
the clinical presentation, emphasizing the influence of
other genetic or environmental metabolic factors on the
life history of this semidominantly inherited disease.Abbreviations
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